Functional assessment of TAS1553 as entry point for synergistic drug interactions with the CDC7-ATR-CHK1 axis in vitro and in vivo

14 November 2023 → 13 November 2025
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Cell death
    • Cell growth and development
    • Cancer biology
    • Cancer therapy
neuroblastoma synergistische drug combinaties relication stress
Project description

Neuroblastoma is a pediatric tumor arising from progenitors of the peripheral nervous system. Half of the patients present with an aggressive form that is difficult to treat resulting in poor survival. Treatment of aggressive neuroblastoma is very intensive with many toxic side effects even in the long term for the patients who survive the disease. In this study, the main goal is to explore the therapeutic potential of pharmacological targeting the replicative stress signaling pathway in high-risk neuroblastoma. We will particularly focus here on new generation drugs that can induce synergistic effects in combination. Extensive preclinical work in vitro and in vivo using mouse models will form the basis to initiate a phase 1 clinical trial.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the authority can be held responsible for them.